STUDY FINDS CILOSTAZOL LOWERS RESTENOSIS RATE IN KIDNEY DISEASE PATIENTS AFTER ANGIOPLASTY

Main Menu | News By Date | News By Supplier | News By Category | About Us

STUDY FINDS CILOSTAZOL LOWERS RESTENOSIS RATE IN KIDNEY DISEASE PATIENTS AFTER ANGIOPLASTY
18 February 2007 - Emory University

According to the National Kidney Foundation, more than 20 million Americans (one in nine adults) have chronic kidney disease. Many of these people also have heart disease and undergo percutaneous coronary intervention, in which angioplasty and stenting are employed to widen narrowed blood vessels. CKD places these patients at increased risk for restenosis, the renarrowing of blood vessels after PCI.

At a poster session today at the American College of Cardiology's 54th Annual Scientific Sessions in Orlando, Emory biostatistician Jovonne K. Foster reported on Emory research which shows the drug cilostazol can significantly help reduce restenosis in patients with heart disease and CKD.

"Even a small reduction in kidney function is associated with a higher rate of cardiovascular events. There is a greater risk of heart disease as kidney disease worsens" says Claudine T. Jurkovitz, MD, MPH, Assistant Professor of Cardiology at Emory School of Medicine and one of the authors of the research presented today. "People with CKD have a higher incidence of restenosis and their risk of death after percutaneous coronary intervention also is increased."

The Cilostazol for RESTenosis trial had previously shown that patients treated with cilostazol after PCI and stenting had a significantly lower rate of restenosis than patients treated with placebo, but these findings did not evaluate the effect of cilostazol on restenosis in patients with CKD. To that end, Emory researchers analyzed a total of 705 patients enrolled in CREST, using creatinine levels to calculate glomerular filtration rates to determine which patients had CKD. They then documented restenosis in this population, using six month post PCI angiograms. The results showed that patients with CKD treated with placebo had a 36.6 percent in-segment restenosis rate while those treated with cilostazol had only a 15.2 percent restenosis rate.

"We conclude that CKD patients may benefit from treatment with cilostazol after PCI. Our findings could be of significant public health importance, considering the high prevalence of CKD in the US and the poor long-term outcome of these patients following PCI," says Dr. Jurkovitz.

The Emory team of researchers also included Karen M Parker, BS; Grant T Anderson, BA; Paul Kolm, Ph.D; Nancy V Murrah, RN,BSN; Ziyad Ghazzal, MD, William S. Weintraub, MD, and John S Douglas Jr, MD. Dr. Douglas disclosed a commercial relationship with Otsuka America Pharmaceutical, Inc.

http://www.emory.edu

About: Emory University
Emory University is home to nine major academic divisions, numerous centres for advanced study, and a host of prestigious affiliated institutions. In addition to Emory College, the University encompasses a graduate school of arts and sciences; professional schools of medicine, theology, law, nursing, public health, and business; and Oxford College, a two-year undergraduate division on the original campus of Emory in Oxford, Ga.

Emory was founded at Oxford by the Methodist Church in 1836. Led by President James W. Wagner, an award-winning teacher and scholar, the University has 11,300 students and 2,500 faculty members who represent all regions of the United States and more than 100 foreign nations.

Emory University is known for its demanding academics, outstanding undergraduate college of arts and sciences, highly ranked professional schools and state-of-the-art research facilities. For more than a decade Emory has been named one of the country's top 25 national universities by U.S. News & World Report. In addition to its nine schools, the university encompasses The Carter Center, Yerkes National Primate Research Center and Emory Healthcare, a comprehensive metropolitan health care system.

More News:
  • For February 2007
  • From Emory University
  • For University